Results 81 to 90 of about 50,123 (191)
Nonencapsulated
mBio, 2016 While significant protection from pneumococcal disease has been achieved by the use of polysaccharide and polysaccharide-protein conjugate vaccines, capsule-independent protection has been limited by serotype replacement along with disease caused by ...
Lance E. Keller +2 more
doaj +1 more source
European Journal of Haematology, Volume 116, Issue 4, Page 336-349, April 2026.ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot +3 more
wiley +1 more source
European Journal of Neurology, Volume 33, Issue 4, April 2026.This 36‐month prospective study of 34 symptomatic SMA patients (ages 6.9–50.9 years) found significant motor and quality of life improvements with risdiplam treatment. Treatment‐naïve patients showed notable gains in MFM‐32 and RULM scores, while those switching therapies improved in MFM‐32.
Pak On Patrick Yee +16 more
wiley +1 more source
The New Era of Pneumococcal Vaccination in Adults: What Is Next?
VaccinesStreptococcus pneumoniae remains the leading cause of community-acquired pneumonia in adults and bacterial meningitis in children worldwide. In addition to pneumonia, invasive pneumococcal diseases (IPDs), such as bacteremia and meningitis, pose a ...
Lale Ozisik
doaj +1 more source
Analysis of pilot data assessing vaccine hesitancy in an urban clinic setting [PDF]
, 2018 Widespread use of childhood vaccination has significantly reduced the burden of childhood disease, however a subset of parents are choosing to delay or refuse available vaccines.
Williams, Amelia
core
Accelerating vaccine development and deployment: report of a Royal Society satellite meeting. [PDF]
, 2011 The Royal Society convened a meeting on the 17th and 18th November 2010 to review the current ways in which vaccines are developed and deployed, and to make recommendations as to how each of these processes might be accelerated.
Bregu, Migena +3 more
core +2 more sources
Preventing First and Further Decompensation in Advanced Chronic Liver Disease
Liver International, Volume 46, Issue 4, April 2026.ABSTRACT Advanced chronic liver disease (ACLD) remains a major cause of global morbidity and mortality. Preventing hepatic decompensation—both the first event and subsequent recurrences—has become a central therapeutic goal to prolong survival. The transition from the compensated phase (cACLD) to the decompensated phase (dACLD) is driven by clinically ...
Leonardo Corrêa Süffert +2 more
wiley +1 more source
Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective
BMC Infectious Diseases, 2012 Background The burden of invasive pneumococcal disease in young children decreased dramatically following introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). The epidemiology of S.
Weil-Olivier Catherine +4 more
doaj +1 more source
Emerging Challenges and Opportunities in Infectious Disease Epidemiology. [PDF]
, 2019 Much of the intellectual tradition of modern epidemiology stems from efforts to understand and combat chronic diseases persisting through the 20th century epidemiologic transition of countries such as the United States and United Kingdom.
Lewnard, Joseph A, Reingold, Arthur L
core
Pneumococcal serotypes in children in 4 European countries [PDF]
, 2010 After heptavalent pneumococcal conjugate vaccine (PCV7) was marketed in France, Spain, Belgium, and England and Wales (United Kingdom), invasive disease from non-PCV7 serotypes (NVT) increased. Adjusted serotype-specific incidences among children
Fenoll, Asuncion +8 more
core +3 more sources